Cirius Therapeutics

Cirius Therapeutics, founded in Michigan, is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for chronic metabolic diseases caused by insulin resistance. Their core mission is to modify metabolism to treat conditions such as Type 2 Diabetes, the metabolic consequences of obesity, and MASLD/MASH. The company focuses on creating insulin sensitizers, with their leading product being Azemiglitazone, aimed at improving insulin sensitivity and addressing non-alcoholic steatohepatitis (NASH).

Notable figures affiliated with Cirius Therapeutics include experienced professionals in the pharmaceutical industry and key investors who support their mission. The company has achieved significant milestones in clinical trials, particularly with Azemiglitazone showing promising results in improving lean muscle mass and metabolic health. Cirius Therapeutics' impact lies in its potential to offer groundbreaking treatments for widespread metabolic disorders, contributing to better health outcomes and quality of life for patients globally.